DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Brokerages

Posted by Brian Himes on Jul 19th, 2026

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty-seven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, twenty-one have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $85.36.

DXCM has been the topic of a number of analyst reports. UBS Group set a $95.00 price objective on shares of DexCom in a research note on Wednesday, June 10th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Monday, May 18th. Raymond James Financial reissued a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a research report on Monday, June 8th. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price on the stock in a research report on Tuesday, March 24th. Finally, Sanford C. Bernstein set a $77.00 target price on DexCom in a report on Friday, May 1st.

Check Out Our Latest Report on DXCM

Insider Activity at DexCom

In other news, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at approximately $7,326,353. This represents a 4.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,750 shares of company stock worth $5,163,241 over the last ninety days. 0.28% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DexCom

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after purchasing an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in DexCom by 6.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after buying an additional 516,526 shares during the last quarter. Norges Bank bought a new position in shares of DexCom in the fourth quarter valued at $483,356,000. Invesco Ltd. grew its holdings in shares of DexCom by 14.8% during the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after buying an additional 686,228 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its position in shares of DexCom by 7.6% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock worth $207,613,000 after acquiring an additional 220,313 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Down 1.7%

Shares of DXCM opened at $76.65 on Friday. The stock’s 50-day moving average price is $71.16 and its two-hundred day moving average price is $68.73. DexCom has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a market capitalization of $29.58 billion, a PE ratio of 32.76, a PEG ratio of 1.26 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the company earned $0.32 earnings per share. The firm’s revenue was up 15.0% compared to the same quarter last year. On average, analysts anticipate that DexCom will post 2.57 EPS for the current year.

DexCom Company Profile

(Get Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.